HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J8655 | Netupitant/palonostron | Akynzeo | 300mg/0.5 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Yes | 2014 | Jan. 1, 2016 | In Use | ||
Q9978 | Netupitant/palonostron | Akynzeo | 300mg/0.5 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Yes | 2014 | July 1, 2015 | Dec. 31, 2015 | No Longer Used | |
NA | Nilotinib | Tasigna | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2007 | In Use | |||
NA | Nilotinib | Tasigna | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2007 | In Use | |||
NA | Nilutamide | Anadron, Nilandron | 150 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1996 | In Use | ||||
NA | Nintedanib | Ofev | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
NA | Nintedanib | Ofev | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
NA | Niraparib | Zejula | 100 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
Niraparib and Abiraterone | Akeega | Multiple | Chemotherapy | Androgen Receptor Inhibitor, Enzyme Inhibitor | CYP 17, PARP | Yes | 2023 | In Use | ||||
C9453 | Nivolumab | Opdivo | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | July 1, 2015 | In Use | ||
J9299 | Nivolumab | Opdivo | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan. 1, 2016 | In Use | ||
J9298 | Nivolumab & relatlimab-rmbw | Opdualag | 3mg/1mg | Immunotherapy | Checkpoint Inhibitor, Monoclonal Antibody | PD-1, LAG3 | No | 2022 | Sept. 27, 2022 | In Use | ||
C9021 | Obinutuzumab | Gazyva | 10 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2013 | April 4, 2014 | Dec. 31, 2014 | No Longer Used | |
J9301 | Obinutuzumab | Gazyva | 10 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2013 | Jan. 1, 2015 | In Use | ||
C9260 | Ofatumumab | Arzerra | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2009 | April 1, 2010 | Dec. 31, 2010 | No Longer Used | |
J9302 | Ofatumumab | Arzerra | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2009 | Jan. 1, 2011 | In Use | ||
J9285 | Olaratumab | Lartruvo | 10 mg | Immunotherapy | Monoclonal Antibody | PDGFR | No | 2016 | April 1, 2017 | In Use | ||
Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
C9297 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | April 1, 2013 | Dec. 31, 2013 | No Longer Used | |
J9262 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Jan. 1, 2014 | In Use | ||
J2405 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 1 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1991 | Jan. 1, 1993 | In Use | ||
Q0179 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 8 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1991 | April 1, 1998 | Dec. 31, 2011 | No Longer Used | |
S0119 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 4 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1991 | Jan. 1, 2012 | In Use | ||
S0181 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 4 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1991 | Jan. 1, 2002 | Dec. 31, 2011 | No Longer Used |
Found 716 results in 3 milliseconds — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.